FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

FDA Project Team supports the company's proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment schedule, and primary endpoint Final Protocol submission ...

Mural Oncology (NASDAQ:MURA – Get Free Report) is one of 1,048 public companies in the “Pharmaceutical preparations” industry ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Reaches Alignment with FDA Regarding Phase 3 Trial Plan On November 25, 2024, Imunon, Inc. (NASDAQ:IMNN) announced it had reached alignment with ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

A team of Rice University bioengineers has developed a mathematical model that clarifies why interleukin-12 (IL-12)—a potent immune-boosting protein that holds promise for cancer treatment ...

The anchored strategy drives local anti-tumor activity, similar to antibody drug conjugates, while limiting systemic toxicity. The company’s lead asset, ANK-101, is an interleukin-12 (IL-12) ...

The molecular mechanisms of HSP47 induction in intestinal fibrosis related to CD, however, remain unclear. Here we investigated the role of interleukin (IL)-17A-induced HSP47 expression in intestinal ...

Entyvio is given as an IV infusion at a clinic every eight weeks. Stelara, also known as ustekinumab, is a monoclonal antibody that targets specific proteins called interleukin-12 (IL-12) and ...

A protein named interleukin-12 (IL-12) is known to successfully activate anti-tumour immune cells against several cancers.

Over the last decade, mouse models of intestinal inflammation have provided invaluable tools to identify cytokines that drive the inflammatory response. Amongst these interleukin 12 (IL12), through ...

Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC ...